T-cell COVID vaccine study for healthy adults
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new COVID-19 vaccine designed to teach your immune system (T-cells) to fight the coronavirus. It is mainly for healthy adults who are not recently infected or vaccinated, to see how safe it is and how your immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Live in the Philippines and sign the study consent form
- Have a negative COVID-19 PCR test at screening
- Have not had a COVID-19 vaccine recently: no COVID shots at all, or if vaccinated before, your last dose must be at least 6 months ago (for common vaccines like AstraZeneca, Pfizer, Moderna, or J&J)
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new COVID-19 vaccine called VYD2311, alone or with another COVID-19 vaccine, in healthy adults. The goal is to see if it is safe and helps your body fight the virus.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
This Phase 3 trial tests a booster vaccine made from a three-part COVID-19 protein (aimed at XBB, BA.5, and Delta) to see how well it works and is tolerated. It may help adults who are due for a COVID-19 booster, including people with certain health conditions, depending on screening results.
This Phase 2 study tests a booster vaccine made from a COVID-19 protein (XBB + prototype) to help your immune system respond better. You may be able to join if you’re an adult who is due for a booster and meets health and safety screening checks.
This trial tests a COVID-19 vaccine in healthy adults to see how well it works. It may be an option if you are not at higher risk for severe COVID-19 and have not had COVID-19 in the past 6 months.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Hear when a new Coronavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.